Document is current

Article History

Accepted: 27 January 2025

First Online: 23 February 2025

Declarations

:

: The study was approved by the Institutional Review Board with a waiver of consent.

: Not applicable.

: The model codes that support the findings of this study are accessible upon reasonable request by contacting the corresponding author.

: The data and material are accessible upon reasonable request by contacting the corresponding author.

: This research included two studies approved by the CCHMC institutional review board with waiver of consent: “Pharmacokinetics of β-lactams in Critically Ill Pediatric Patients during Different Stages of Sepsis” (IRB #2018-3245), and “Taking Focus 2” (IRB #2018-0724).

: R Morales Junior, HR Hambrick, and S Tang Girdwood conceptualized the study. HR Hambrick, KE Pavia, KM Paice, KA Krallman, L Johnson, M Collins, A Gibson, and C Curry collected the data. P Tang and E Schuler conducted the laboratory analyses. R Morales Junior, T Mizuno, and S Tang Girdwood analyzed the pharmacokinetic data. R Morales Junior and HR Hambrick wrote the original draft of the manuscript, and all authors contributed to reviewing and editing the manuscript. J Kaplan, S Goldstein, and S Tang Girdwood supervised the project.

: This work was generously supported by the National Institutes of Health, including funding from the National Institute of General Medical Sciences under an R35 award (R35GM14670), the Eunice Kennedy Shriver National Institute of Child Health and Human Development T32 Training Program in Pediatric Clinical and Developmental Pharmacology (T32HD069054), and the National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007695).

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.